Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin plus doxorubicin versus doxorubicin alone in first-line metastatic leiomyosarcoma
NL-OMON61013Phase 3Active, not recruiting
- Sponsor
- PharmaMar
- Start
- Oct 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in leiomyosarcoma (LMS) comparing Lurbinectedin plus doxorubicin with Doxorubicin alone (2 arms). Primary endpoint: Progression-free survival by Independent Review Committee. Started Oct 2025; status: active, not recruiting.
02
Drugs
lurbinectedindoxorubicin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NL-OMON61013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61013.